Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 7/20 | 0.55 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005460 | 0.93 | FYN (0.53) | FYNPARP1 | |
| SCHEMBL13005464 | 0.92 | FYN (0.49) | FYNPARP1 | |
| SCHEMBL13060639 | 0.86 | FYN (0.55) | FYNCAMK2DPARP1MAP4K4RAD52 | |
| SCHEMBL13005465 | 0.85 | HPGD (0.57) | FYN | |
| SCHEMBL13005545 | 0.83 | UTS2R (0.50) | — | |
| SCHEMBL27317323 | 0.82 | PARP1 (0.59) | FYNCAMK2DPARP1MAP4K4RAD52 | |
| SCHEMBL17154227 | 0.82 | FYN (0.49) | FYNCAMK2DPARP1MAP4K4RAD52 | |
| SCHEMBL26378205 | 0.81 | HPGD (0.59) | PARP1MMP1MMP2MMP9MMP14 | |
| SCHEMBL13005455 | 0.81 | HPGDS (0.45) | — | |
| SCHEMBL13005436 | 0.80 | HDAC4 (0.45) | PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851637-B2 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |